Global Antibiotics Market Size 2021-2028


Pune, India, February 17, 2022 (GLOBE NEWSWIRE) — The global antibiotics market size was USD 37.35 billion in 2020. It is expected to grow from USD 38.08 billion in 2021 to USD 45.30 billion in 2028 at a CAGR of 2.5% during the period 2021-2028.

We follow a creative review technique that remembers the triangulation of information for the premise of basic and hierarchical methodologies. We are conducting a broad review essential to approve the projected market figures. The information used to assess the estimation of the various portions at the national, provincial and global levels is gathered through interviews with numerous alleged partners. We also obtain data from paid databases, industry journals, SEC filings, and other genuine assets. The report incorporates some intricacies, like drivers, open houses, challenges, and elements of the Antibiotics market.

Industry development:

  • May 2021: Sandoz has announced its intention to expand antibiotic production capacities in Palafolls and Kundl. It aims to improve its ability to deliver high quality medicines to patients, while remaining cost competitive in the industry.
  • July 2019: Pfizer Inc. and HERTFORDSHIRE, England & PITTSBURGH & Mylan NV have agreed to combine Upjohn and Mylan to develop a new company. This development would help them increase their business and provide high quality medicines to patients.

Request a sample copy of the research report:

Antibiotics Market Growth Drivers:

  • Rising prevalence of multiple bacterial infections such as skin infections, urinary tract infections (UTIs), tuberculosis and respiratory infections across the world is expected to propel the growth of the antibiotics market in the near future.
  • At the same time, the growing burden of bacterial infections is expected to be the most common cause of death by 2050. According to the World Health Organization, approximately 50% of women have suffered from a UTI at some point of their life.
  • The demand for antibiotics is increasing dramatically due to the increasing incidence of infectious diseases. The high prevalence of infectious diseases, such as lower respiratory tract infections, pneumonia, malaria, and tuberculosis, is also fueling the growth of the market.
  • The increasing disease burden is forcing governmental and non-governmental organizations to invest in R&D initiatives and spur the development of new antibiotics and supportive regulatory policies to speed up the approval process and research funding.

To learn more about the short and long term impact of COVID-19 on this market, please visit:

Market segments:

  • By drug class, this market is divided into penicillin, cephalosporin, aminoglycosides, tetracycline, macrolides, fluoroquinolones, sulfonamides and others. Of these, the penicillin segment has generated 29.7% in terms of antibiotics market share in 2020 and remains in the lead.
  • Mixed cell divider inhibitors led the market in 2020 with a 52.1% share and are expected to maintain their lead throughout the conjecture period. The maximum use according to the design of the remedies and the huge government subsidies are the main variables driving the fragment.
  • The fragment of RNA amalgamation inhibitors is expected to see considerable development during the conjecture period due to the increase in the number of article submissions and R&D efforts. For example, in November 2018, Cosmo Pharmaceuticals NV introduced Aemcolo (rifamycin) as extended release tablets for the treatment of traveler’s diarrhea in the United States.

Quick Buy Antibiotics Market Report Research

Regional outlook-

North America to dominate fueled by development of new antibiotics

Geographically, in 2020 North America bought $16.81 billion in terms of income. It is expected to stay at the forefront in the coming years due to the introduction of various new drugs by leading companies present in this region.

The antibiotics market players in the country are largely focusing on improving the new enemy of infectious drugs, and they are additionally adopting different development methodologies. Hence, this is likely to boost the market in the country. For example, in August 2019, the United States Food and Drug Administration approved xenleta (lefamulin) to treat adults with local bacterial pneumonia.

The United States holds the major share of the market in the North American region owing to how the United States has the highest anti-infective approval rate in the North American region. The United States is one of the countries hardest hit by the COVID-19 outbreak.

You have a question ? Ask our experts:

A list of reputable suppliers in the antibiotics market:

  • Pfizer Inc. (New York, USA)
  • Abbott (Illinois, USA)
  • GlaxoSmithKline plc. (London, UK)
  • Sanofi (Paris, France)
  • Novartis AG (Basel, Switzerland)
  • Bayer AG (Leverkusen, Germany)
  • Bristol-Myers Squibb Company (New York, USA)
  • Merck & Co., Inc. (Kenilworth, USA)
  • Astellas Pharma Inc. (Tokyo, Japan)
  • Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.) (New Brunswick, USA)

About Us:

Fortune Business Insights™ provides accurate data and innovative business analytics, helping organizations of all sizes make the right decisions. We adapt innovative solutions to our clients, helping them to meet various challenges specific to their activities. Our goal is to give them holistic market intelligence, providing them with granular insight into the market they operate in.

Contact us:

United States: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

E-mail: [email protected]


About Author

Comments are closed.